The £80m (€131.3m) UK-based Boehringer Ingelheim defined benefit pension fund has reappointed Schroder Investment Management following a review of its portfolio.

The pension fund of the ethical pharmaceutical manufacturer had placed Schroder, its sole manager, under review last year, partly because it decided to re-assess its investment strategy under the best value regime. It also had concerns about Schroder's performance over the last two to three years.